BOSTON, Jan. 08, 2026 -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed...
Us2.ai receives FDA clearance for Us2.v2,transforming cardiovascular ultrasound analysis
News | 04. 04. 2024
Us2.ai
Singapore – April 5, 2024 – Us2.ai, a leading MedTech firm backed by prominent investors including IHH Healthcare, Heal Partners, Peak XV Partners (formerly Sequoia India) and EDBI, announces FDA clearance for Us2.v2, featuring 45 automated echo parameters, including strain analysis, marking a significant stride in medical innovation.
